LIVIVO - Search results -

Search results

Result 1 - 10 of total 6669

Search options

Article ; Online: Cross-protection induced by highly conserved human B, CD4

Prakash, Swayam / Dhanushkodi, Nisha R / Zayou, Latifa / Ibraim, Izabela Coimbra / Quadiri, Afshana / Coulon, Pierre Gregoire / Tifrea, Delia F / Suzer, Berfin / Shaik, Amin Mohammed / Chilukuri, Amruth / Edwards, Robert A / Singer, Mahmoud / Vahed, Hawa / Nesburn, Anthony B / Kuppermann, Baruch D / Ulmer, Jeffrey B / Gil, Daniel / Jones, Trevor M / BenMohamed, Lbachir

Frontiers in immunology

2024 Volume 15, Page(s) 1328905

Abstract: ... Methods: We designed a multi-epitope-based coronavirus vaccine that incorporated B, CD4: Results ... CD8: Conclusion: A multi-epitope pan-variant SARS-CoV-2 vaccine bearing conserved human B- and T ...

Abstract	Background: The coronavirus disease 2019 (COVID-19) pandemic has created one of the largest global health crises in almost a century. Although the current rate of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections has decreased significantly, the long-term outlook of COVID-19 remains a serious cause of morbidity and mortality worldwide, with the mortality rate still substantially surpassing even that recorded for influenza viruses. The continued emergence of SARS-CoV-2 variants of concern (VOCs), including multiple heavily mutated Omicron sub-variants, has prolonged the COVID-19 pandemic and underscores the urgent need for a next-generation vaccine that will protect from multiple SARS-CoV-2 VOCs. Methods: We designed a multi-epitope-based coronavirus vaccine that incorporated B, CD4 Results: The pan-variant SARS-CoV-2 vaccine (i) is safe , (ii) induces high frequencies of lung-resident functional CD8 Conclusion: A multi-epitope pan-variant SARS-CoV-2 vaccine bearing conserved human B- and T- cell epitopes from structural and non-structural SARS-CoV-2 antigens induced cross-protective immunity that facilitated virus clearance, and reduced morbidity, COVID-19-related lung pathology, and death caused by multiple SARS-CoV-2 VOCs.
MeSH term(s)	Animals ; Humans ; Mice ; CD4-Positive T-Lymphocytes ; CD8-Positive T-Lymphocytes ; COVID-19/prevention & control ; COVID-19 Vaccines/immunology ; Epitopes, T-Lymphocyte/genetics ; Pandemics ; SARS-CoV-2/genetics ; Cross Protection
Chemical Substances	COVID-19 Vaccines ; Epitopes, T-Lymphocyte
Language	English
Publishing date	2024-01-22
Publishing country	Switzerland
Document type	Journal Article ; Research Support, N.I.H., Extramural
ZDB-ID	2606827-8
ISSN	1664-3224 ; 1664-3224
ISSN (online)	1664-3224
ISSN	1664-3224
DOI	10.3389/fimmu.2024.1328905
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article: Extranodal Diffuse Large B-cell Lymphoma With Primary Clinical Presentation as Acute Cholecystitis: A Case Report.

Rössler, Fabian / Sachs, Alexandra / Bieri, Uwe / Kuzmanic, Boris / Ballova, Veronika / Schneider, Ulrich / Singer, Gad / Nocito, Antonio

Cureus

2023 Volume 15, Issue 4, Page(s) e37552

Abstract: This case describes a rare presentation of a diffuse large B-cell lymphoma not otherwise specified ...

Abstract	This case describes a rare presentation of a diffuse large B-cell lymphoma not otherwise specified (DLBC NOS) in the gallbladder. We report the case of an 89-year-old male who initially presented with a two-week history of weakness and abdominal discomfort. We performed laparoscopic cholecystectomy for suspicion of acute cholecystitis. After the initial uneventful course, readmission occurred for persisting weakness a few weeks after surgery. Computed tomography revealed progressive retroperitoneal lymphadenopathy. With new emerging neurological symptoms, taking into account the histopathological findings of the gallbladder specimen, the diagnosis of DLBCL NOS was confirmed. Due to the rapid clinical deterioration and extranodal involvement, the patient opted against further therapy. When the suspicion of cholecystitis is inconclusive, rare differential diagnoses need to be considered. This analysis may improve the understanding of the presentation and course of DLBC NOS in abdominal organs and could form the basis for a systematic review to improve diagnosis and therapy.
Language	English
Publishing date	2023-04-14
Publishing country	United States
Document type	Case Reports
ZDB-ID	2747273-5
ISSN	2168-8184
ISSN	2168-8184
DOI	10.7759/cureus.37552
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Mucosal CCL28 Chemokine Improves Protection against Genital Herpes through Mobilization of Antiviral Effector Memory CCR10+CD44+ CD62L-CD8+ T Cells and Memory CCR10+B220+CD27+ B Cells into the Infected Vaginal Mucosa.

Journal of immunology (Baltimore, Md. : 1950)

2023 Volume 211, Issue 1, Page(s) 118–129

Abstract: ... the role of the CCL28/CCR10 chemokine axis in mobilizing protective antiviral B and T cell subsets ... CCR10+B220+CD27+ B cells in the VM of HSV-infected ASYMP mice. Inversely, compared with wild-type C57BL/6 mice ... effector memory CCR10+CD44+CD62L-CD8+ TEM cells and of memory CD27+B220+ B cells in the infected VM ...

Abstract	Four major mucosal-associated chemokines, CCL25, CCL28, CXCL14, and CXCL17, play an important role in protecting mucosal surfaces from infectious pathogens. However, their role in protection against genital herpes remains to be fully explored. The CCL28 is a chemoattractant for the CCR10 receptor-expressing immune cells and is produced homeostatically in the human vaginal mucosa (VM). In this study, we investigated the role of the CCL28/CCR10 chemokine axis in mobilizing protective antiviral B and T cell subsets into the VM site of herpes infection. We report a significant increase in the frequencies of HSV-specific memory CCR10+CD44+CD8+ T cells, expressing high levels of CCR10, in herpes-infected asymptomatic (ASYMP) women compared with symptomatic women. Similarly, a significant increase in the CCL28 chemokine (a ligand of CCR10), was detected in the VM of herpes-infected ASYMP C57BL/6 mice, associated with the mobilization of high frequencies of HSV-specific effector memory CCR10+CD44+CD62L-CD8+ TEM cells and memory CCR10+B220+CD27+ B cells in the VM of HSV-infected ASYMP mice. Inversely, compared with wild-type C57BL/6 mice, the CCL28 knockout (CCL28-/-) mice (1) appeared to be more susceptible to intravaginal infection and reinfection with HSV type 2, and (2) exhibited a significant decrease in the frequencies of HSV-specific effector memory CCR10+CD44+CD62L-CD8+ TEM cells and of memory CD27+B220+ B cells in the infected VM. These findings suggest a critical role of the CCL28/CCR10 chemokine axis in the mobilization of antiviral memory B and T cells within the VM to protect against genital herpes infection and disease.
MeSH term(s)	Humans ; Female ; Mice ; Animals ; Herpes Genitalis ; Antiviral Agents/metabolism ; Mice, Inbred C57BL ; CD8-Positive T-Lymphocytes ; Herpesvirus 2, Human ; Mucous Membrane ; Antiviral Restriction Factors ; Receptors, CCR10/metabolism ; Chemokines, CC/metabolism ; Hyaluronan Receptors/metabolism
Chemical Substances	Antiviral Agents ; Antiviral Restriction Factors ; CCR10 protein, human ; Receptors, CCR10 ; CCL28 protein, human ; Chemokines, CC ; CD44 protein, human ; Hyaluronan Receptors
Language	English
Publishing date	2023-05-22
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
ZDB-ID	3056-9
ISSN	1550-6606 ; 0022-1767 ; 1048-3233 ; 1047-7381
ISSN (online)	1550-6606
ISSN	0022-1767 ; 1048-3233 ; 1047-7381
DOI	10.4049/jimmunol.2300093
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ud II Zs.37: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MG 28: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Genomic Profiling Reveals Differences in Primary Central Nervous System Lymphoma and Large B-Cell Lymphoma, With Subtyping Suggesting Sensitivity to BTK Inhibition.

Severson, Eric A / Haberberger, James / Hemmerich, Amanda / Huang, Richard S P / Edgerly, Claire / Schiavone, Kelsie / Najafian, Adib / Hiemenz, Matthew / Lechpammer, Mirna / Vergilio, Jo-Anne / Lesser, Glenn / Strowd, Roy / Elvin, Julia / Ross, Jeffrey S / Hegde, Priti / Alexander, Brian / Singer, Samuel / Ramkissoon, Shakti

The oncologist

2022 Volume 28, Issue 1, Page(s) e26–e35

Abstract: Background: B-cell primary central nervous system (CNS) lymphoma (PCL) is diffuse large B-cell ... of germinal center B-cell like (GCB) and non-GCB subtypes and molecular subtypes, particularly MCD and EZH subtypes ... between PCL and DLBCL.: Materials and methods: Sixty-nine cases of B-cell PCL, 36 cases of secondary ...

Abstract	Background: B-cell primary central nervous system (CNS) lymphoma (PCL) is diffuse large B-cell lymphoma (DLBCL) confined to the CNS. Less than 50% of patients with PCL achieve complete remission with current therapies. We describe the findings from comprehensive genomic profiling (CGP) of a cohort of 69 patients with PCL, 36 cases of secondary CNS lymphoma (SCL), and 969 cases of DLBCL to highlight their differences and characterize the PCL cohort. In addition, we highlight the differences in frequency of germinal center B-cell like (GCB) and non-GCB subtypes and molecular subtypes, particularly MCD and EZH subtypes, between PCL and DLBCL. Materials and methods: Sixty-nine cases of B-cell PCL, 36 cases of secondary CNS lymphoma (SCL), and 969 cases of DLBCL were evaluated by CGP of 405 genes via DNAseq and 265 genes via RNAseq for fusions (FoundationOne Heme). Tumor mutational burden (TMB) was calculated from 1.23 Mb of sequenced DNA. Results: Genomic alterations with significant differences between PCL and DLBCL included MYD88, ETV6, PIM1, PRDM1, CXCR4, TP53, and CREBBP, while only MYD88 was significantly different between SCL and DLBCL. PCL cases were significantly enriched for the MCD molecular subtypes, which have an excellent response to BTKi. We report a patient with a durable complete response to BTKi consistent with their genomic profile. EBV status, CD274 amplification, and TMB status suggest that 38% of PCL patients may benefit from ICPI; however further study is warranted. Conclusion: CGP of PCLs reveals biomarkers, genomic alterations, and molecular classifications predictive of BTKi efficacy and potential ICPI efficacy. Given the limitations of standard of care for PCL, CGP is critical to identify potential therapeutic approaches for patients in this rare form of lymphoma.
MeSH term(s)	Humans ; Prognosis ; Myeloid Differentiation Factor 88 ; Lymphoma, Large B-Cell, Diffuse/drug therapy ; Lymphoma, Large B-Cell, Diffuse/genetics ; Germinal Center/pathology ; Biomarkers, Tumor/genetics ; Central Nervous System/pathology
Chemical Substances	Myeloid Differentiation Factor 88 ; Biomarkers, Tumor
Language	English
Publishing date	2022-11-07
Publishing country	England
Document type	Case Reports ; Journal Article
ZDB-ID	1409038-7
ISSN	1549-490X ; 1083-7159
ISSN (online)	1549-490X
ISSN	1083-7159
DOI	10.1093/oncolo/oyac190
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4845: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 494: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The intrinsic kinase activity of BRD4 spans its BD2-B-BID domains.

Weissman, Jocelyn D / Singh, Amit K / Devaiah, Ballachanda N / Schuck, Peter / LaRue, Ross C / Singer, Dinah S

The Journal of biological chemistry

2021 Volume 297, Issue 5, Page(s) 101326

Abstract: ... B motif (aa 503-548) disrupts BRD4's dimerization. BRD4 kinase activity maps to amino acids 351 ... to 598, which span bromodomain-2, the B motif, and the BID domain (BD2-B-BID) and contributes ...

Abstract	Bromodomain protein 4 (BRD4) is a transcriptional and epigenetic regulator that is a therapeutic target in many cancers and inflammatory diseases. BRD4 plays important roles in transcription as an active kinase, which phosphorylates the carboxy-terminal domain (CTD) of RNA polymerase II (Pol II), the proto-oncogene c-MYC, and transcription factors TAF7 and CDK9. BRD4 is also a passive scaffold that recruits transcription factors. Despite these well-established functions, there has been little characterization of BRD4's biophysical properties or its kinase activity. We report here that the 156 kD mouse BRD4 exists in an extended dimeric conformation with a sedimentation coefficient of ∼6.7 S and a high frictional ratio. Deletion of the conserved B motif (aa 503-548) disrupts BRD4's dimerization. BRD4 kinase activity maps to amino acids 351 to 598, which span bromodomain-2, the B motif, and the BID domain (BD2-B-BID) and contributes to the in vivo phosphorylation of its substrates. As further assessed by analytical ultracentrifugation, BRD4 directly binds purified Pol II CTD. Importantly, the conserved A motif of BRD4 is essential for phosphorylation of Pol II CTD, but not for phosphorylation of TAF7, mapping its binding site to the A motif. Peptides of the viral MLV integrase (MLVIN) protein and cellular histone lysine methyltransferase, NSD3, which have been shown by NMR to bind to the extra-terminal (ET) domain, also are phosphorylated by BRD4. Thus, BRD4 has multiple distinct substrate-binding sites and a common kinase domain. These results provide new insights into the structure and kinase function of BRD4.
MeSH term(s)	Amino Acid Motifs ; Animals ; Mice ; Nuclear Proteins/chemistry ; Nuclear Proteins/genetics ; Nuclear Proteins/metabolism ; Protein Domains ; Protein Kinases/chemistry ; Protein Kinases/genetics ; Protein Kinases/metabolism ; Protein Multimerization ; Protein Structure, Quaternary ; RNA Polymerase II/chemistry ; RNA Polymerase II/genetics ; RNA Polymerase II/metabolism ; TATA-Binding Protein Associated Factors/chemistry ; TATA-Binding Protein Associated Factors/genetics ; TATA-Binding Protein Associated Factors/metabolism ; Transcription Factor TFIID/chemistry ; Transcription Factor TFIID/genetics ; Transcription Factor TFIID/metabolism ; Transcription Factors/chemistry ; Transcription Factors/genetics ; Transcription Factors/metabolism
Chemical Substances	Brd4 protein, mouse ; Nuclear Proteins ; TAF7 protein, mouse ; TATA-Binding Protein Associated Factors ; Transcription Factor TFIID ; Transcription Factors ; Protein Kinases (EC 2.7.-) ; RNA Polymerase II (EC 2.7.7.-)
Language	English
Publishing date	2021-10-22
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, N.I.H., Intramural
ZDB-ID	2997-x
ISSN	1083-351X ; 0021-9258
ISSN (online)	1083-351X
ISSN	0021-9258
DOI	10.1016/j.jbc.2021.101326
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uc I Zs.108: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Evidence of tenofovir resistance in chronic hepatitis B virus (HBV) infection: An observational case series of South African adults.

Mokaya, Jolynne / Maponga, Tongai G / McNaughton, Anna L / Van Schalkwyk, Marije / Hugo, Susan / Singer, Joshua B / Sreenu, Vattipally B / Bonsall, David / de Cesare, Mariateresa / Andersson, Monique / Gabriel, Shiraaz / Taljaard, Jantje / Barnes, Eleanor / Preiser, Wolfgang / Van Rensburg, Christo / Matthews, Philippa C

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology

2020 Volume 129, Page(s) 104548

Abstract: ... hepatitis B virus (HBV) infection because it is safe, affordable and has a high genetic barrier ...

Abstract	Introduction: Tenofovir disoproxil fumarate (TDF) is widely recommended for treatment of chronic hepatitis B virus (HBV) infection because it is safe, affordable and has a high genetic barrier to resistance. TDF resistance associated mutations (RAMs) have been reported, but data are limited, particularly for Africa. We set out to identify potential RAMs in individuals with detectable HBV viraemia on TDF treatment. Methods: We recruited adults with chronic HBV infection from Cape Town, South Africa, identifying individuals with a TDF resistance phenotype, defined as persistent HBV vireamia despite >12 months of TDF treatment. We sequenced HBV DNA using MiSeq Illumina with whole genome target enrichment, and sought potential TDF RAMs, based on a pre-defined list of polymorphisms. Results: Among 66 individuals with chronic HBV (genotypes A and D), three met our clinical definition for TDF resistance, of whom two were coinfected with HIV. In one participant, the consensus HBV sequence contained nine polymorphisms that have been described in association with TDF resistance. Significant treatment non-adherence in this individual was unlikely, as HIV RNA was suppressed. TDF RAMs were also present in HBV sequences from the other two participants, but other factors including treatment non-adherence may also have had a role in failure of HBV DNA suppression in these cases. Discussion: Our findings add to the evidence that RAMs in HBV reverse transcriptase may underpin a TDF resistant phenotype. This is the first time these RAMs have been reported from Africa in association with clinical evidence of TDF resistance.
MeSH term(s)	Adult ; Antiviral Agents/therapeutic use ; DNA, Viral ; Drug Resistance, Viral ; Hepatitis B virus/genetics ; Hepatitis B, Chronic/drug therapy ; Humans ; South Africa ; Tenofovir/therapeutic use ; Treatment Outcome
Chemical Substances	Antiviral Agents ; DNA, Viral ; Tenofovir (99YXE507IL)
Language	English
Publishing date	2020-07-08
Publishing country	Netherlands
Document type	Journal Article ; Observational Study ; Research Support, Non-U.S. Gov't
ZDB-ID	1446080-4
ISSN	1873-5967 ; 1386-6532
ISSN (online)	1873-5967
ISSN	1386-6532
DOI	10.1016/j.jcv.2020.104548
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3790: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Combination of apremilast and narrowband ultraviolet B light in the treatment of generalized vitiligo in skin phototypes IV to VI: A randomized split-body pilot study.

Kim, Hee J / Singer, Giselle K / Del Duca, Ester / Abittan, Brian J / Chima, Margot A / Kimmel, Grace / Bares, Jennifer / Gagliotti, Matthew / Genece, Jordan / Chu, Justin / Wilding, Gregory / Pavel, Ana B / Guttman-Yassky, Emma / Lebwohl, Mark G

Journal of the American Academy of Dermatology

2021 Volume 85, Issue 6, Page(s) 1657–1660

MeSH term(s)	Humans ; Pilot Projects ; Skin Pigmentation ; Thalidomide/analogs & derivatives ; Thalidomide/therapeutic use ; Treatment Outcome ; Ultraviolet Therapy ; Vitiligo/drug therapy ; Vitiligo/radiotherapy
Chemical Substances	Thalidomide (4Z8R6ORS6L) ; apremilast (UP7QBP99PN)
Language	English
Publishing date	2021-01-10
Publishing country	United States
Document type	Letter ; Randomized Controlled Trial
ZDB-ID	603641-7
ISSN	1097-6787 ; 0190-9622
ISSN (online)	1097-6787
ISSN	0190-9622
DOI	10.1016/j.jaad.2020.12.073
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1540: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Apremilast and narrowband ultraviolet B combination therapy suppresses Th17 axis and promotes melanogenesis in vitiligo skin: a randomized, split-body, pilot study in skin types IV-VI.

Kim, Hee J / Del Duca, Ester / Pavel, Ana B / Singer, Giselle K / Abittan, Brian J / Chima, Margot A / Kimmel, Grace / Bares, Jennifer / Baum, Danielle / Gagliotti, Matthew / Genece, Jordan / Chu, Justin / Lebwohl, Mark G / Guttman-Yassky, Emma

Archives of dermatological research

2022 Volume 315, Issue 2, Page(s) 215–221

Abstract: Improved repigmentation of generalized vitiligo in skin types IV-VI has been reported in clinical response to combined therapy with apremilast and narrowband (NB)-UVB; however, tissue responses to combined therapy versus NB-UVB monotherapy have not been ... ...

Abstract	Improved repigmentation of generalized vitiligo in skin types IV-VI has been reported in clinical response to combined therapy with apremilast and narrowband (NB)-UVB; however, tissue responses to combined therapy versus NB-UVB monotherapy have not been elucidated. We compared the change from baseline in cellular and molecular markers in vitiligo skin after combined therapy versus NB-UVB monotherapy. We assessed lesional and nonlesional skin samples from enrolled subjects and evaluated for immune infiltrates, inflammatory, and melanogenesis-related markers which were compared across different treatment groups. Combined therapy resulted in significant reduction of CD8
MeSH term(s)	Humans ; Vitiligo/drug therapy ; Vitiligo/radiotherapy ; Pilot Projects ; Ultraviolet Therapy/methods ; Skin ; Treatment Outcome ; Combined Modality Therapy
Chemical Substances	apremilast (UP7QBP99PN)
Language	English
Publishing date	2022-03-13
Publishing country	Germany
Document type	Randomized Controlled Trial ; Journal Article
ZDB-ID	130131-7
ISSN	1432-069X ; 0340-3696
ISSN (online)	1432-069X
ISSN	0340-3696
DOI	10.1007/s00403-022-02343-1
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ui VI Zs.10: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Evaluation of Antibody Responses in Patients with B-Cell Malignancies after Two and Three Doses of Anti-SARS-CoV-2 S Vaccination-A Retrospective Cohort Study.

Wirth, Stella Rosa Maria / Podar, Klaus / Pecherstorfer, Martin / Wohlfarth, Philipp / Jaeger, Ulrich / Singer, Josef

Cancers

2023 Volume 15, Issue 2

Abstract: Patients with B-cell malignancies are at a higher risk of severe SARS-CoV-2 infections ... among patients with B-cell malignancies treated at the University Hospital Krems and the University Hospital ... in patients with B-cell malignancies. ...

Abstract	Patients with B-cell malignancies are at a higher risk of severe SARS-CoV-2 infections. Nevertheless, extensive data on the immune responses of hematological patients and the efficacy of the third dose of the vaccine are scarce. The goal of this study was to determine standardized anti-SARS-CoV-2 S antibody levels and to evaluate differences between treatment modalities in response to the second and third vaccines among patients with B-cell malignancies treated at the University Hospital Krems and the University Hospital of Vienna. The antibody levels of a total of 80 patients were retrospectively analyzed. The results indicate a significant increase in antibody production in response to the third vaccination. The highest increases could be observed in patients in a "watchful-waiting" and "off-therapy" setting. Encouragingly, approximately one-third of patients who did not develop antibodies in response to two vaccinations achieved seroconversion after the third vaccination. "Watchful-waiting", "off-therapy" and treatment with BTK inhibitors were indicative for increased antibody response after the third dose compared to anti-CD19 CAR T-cell and anti-CD-20 antibody treatment. In summary, the results of this study underline the pre-eminent role of the need for complete vaccination with three doses for the development of protective immunity in patients with B-cell malignancies.
Language	English
Publishing date	2023-01-14
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2527080-1
ISSN	2072-6694
ISSN	2072-6694
DOI	10.3390/cancers15020524
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Evaluation of Ki-67 as a Prognostic Marker in Diffuse Large B-Cell Lymphoma-A Single-Center Retrospective Cohort Study.

Huber, Fabian / Zwickl-Traxler, Elisabeth / Pecherstorfer, Martin / Singer, Josef

Current oncology (Toronto, Ont.)

2021 Volume 28, Issue 6, Page(s) 4521–4529

Abstract: Background: Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma and ... linear regression analysis was performed, including gender, Ki-67 ≤ 70% or >70%, IPI and presence of B symptoms ...

Abstract	Background: Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma and prognostic information is essential in finding the right treatment. This study evaluated the prognostic significance of Ki-67 in patients with DLBCL. Methods: Patients with DLBCL, treated with first-line R-CHOP, were retrospectively analyzed in groups of high (>70%) and low (≤70%) Ki-67. Parameters of interest were the international prognostic index (IPI), treatment response, progression-free survival (PFS) and overall survival (OS). A chi-squared test or Fisher's exact test was conducted to analyze categorical variables. Kaplan-Meier and log-rank tests were applied for survival analyses. Finally, a multivariate linear regression analysis was performed, including gender, Ki-67 ≤ 70% or >70%, IPI and presence of B symptoms. Results: Overall, 58 patients were included. No significant association was found between Ki-67 status and IPI ( Conclusion: Future studies with larger patient cohorts are needed in order to elucidate the prognostic role of Ki-67 in patients with DLBCL treated with R-CHOP.
MeSH term(s)	Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Humans ; Ki-67 Antigen ; Lymphoma, Large B-Cell, Diffuse/drug therapy ; Prognosis ; Retrospective Studies
Chemical Substances	Ki-67 Antigen ; MKI67 protein, human
Language	English
Publishing date	2021-11-08
Publishing country	Switzerland
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	1236972-x
ISSN	1718-7729 ; 1198-0052
ISSN (online)	1718-7729
ISSN	1198-0052
DOI	10.3390/curroncol28060383
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4305: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito